ERBB2 and gastroesophageal junction adenocarcinoma: Furthermore, T-DXd has also been approved for the treatment of patients with metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who received a prior trastuzumab-based regimen and those with previously treated HER2-mutant metastatic non-small-cell lung cancer (NSCLC), based on the results of the DESTINY-Gastric 01 and DESTINY-Lung01 phase II trials [24,25].